Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing
OSAKA, Japan , /CNW/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary — a milestone that reflects two decades of dedication to improving health outcomes through high-quality, patient-centered research. Since its founding in 2005 in Japan , the company has grown from a small team with a bold vision into a global organization supporting clinical trials in more than 30 countries.
From the beginning, Linical set out to do more than manage clinical studies — the company set out to make a meaningful impact on patients' lives. Over the years, Linical's services have expanded to include full-service clinical trial management, site selection and feasibility, regulatory support, biometrics, pharmacovigilance, and drug development strategies. Throughout this growth, Linical's core mission has remained the same: to advance science while prioritizing patient safety and wellbeing.
"What began as a small startup with a few dedicated professionals from the pharmaceutical industry has grown into a global force in clinical research," said Kazuhiro Hatano , President and CEO of Linical. "We've never lost sight of the fact that at the heart of every clinical trial is a patient who is hoping for a better future. That's what continues to drive us."
Over the past two decades, Linical has supported hundreds of clinical studies across a range of therapeutic areas including oncology, neurology, immunology, and rare diseases. By leveraging technology and data-driven processes, the company has delivered faster study start-up times, improved site performance, and enhanced trial quality. Its investments in decentralized trial capabilities and digital tools have positioned the company at the forefront of innovation, especially in an era where flexibility and accessibility in research are more critical than ever.
The company attributes its success to a collaborative culture, strong partnerships with sponsors and sites, and an unwavering focus on patients. "Clinical research is ultimately about people," added Mr. Hatano. "It's about the people participating in trials, the investigators treating them, and the sponsors developing new therapies. We're proud to be part of that ecosystem, helping turn scientific discovery into real-world impact."
As it marks its 20th year, Linical is also looking ahead. The arrival of artificial intelligence is transforming the clinical research industry. With continued investment in global operations, advanced analytics, and patient-focused technologies, the company plans to further strengthen its ability to deliver efficient, high-quality clinical trials that bring new treatments to market faster.
"We're proud of what we've achieved, but we're even more excited about the future," said Mr. Hatano. "Our work is far from done, and we remain committed to our purpose: improving lives through research."
About Linical:
Linical is a global provider of clinical research services, supporting biopharmaceutical companies in bringing innovative therapies to patients across APAC, Europe , and North America . With a focus on quality, technology, and patient wellbeing, Linical delivers tailored solutions for clinical trials across all phases and numerous therapeutic areas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 hours ago
- Globe and Mail
PCSK9 Inhibitors Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Pipeline, Therapies, and Companies by DelveInsight
"PCSK9 Inhibitors Drugs Market" PCSK9 Inhibitors Companies are Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotechnology, Novo Nordisk, AstraZeneca, Akeso Biopharma, Amgen, Jiangsu Hengrui Medicine Co., Innovent Biologics, LIB Therapeutics, AstraZeneca and Ionis Pharmaceuticals, CiVi Biopharma, and others. (Albany, USA) DelveInsight's ' PCSK9 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 ″ report offers an in-depth understanding of the PCSK9 Inhibitors, historical and forecasted epidemiology as well as the PCSK9 Inhibitors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The PCSK9 Inhibitors market is steadily advancing, driven by evolving treatment strategies and ongoing research. DelveInsight's latest 7MM report offers in-depth insights into key epidemiology trends and market dynamics. To Know in detail about the PCSK9 Inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Some of the key facts of the PCSK9 Inhibitors Market Report: The PCSK9 Inhibitors market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In June 2025, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for the treatment of adults with hyperlipidemia on lipid-lowering therapies, including at least a statin. The CORALreef HeFH and CORALreef AddOn trials successfully met their primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful greater reductions in low-density lipoprotein cholesterol (LDL-C) for enlicitide compared to placebo (CORALreef HeFH) and compared to other oral non-statin therapies (CORALreef AddOn). There were no clinically meaningful differences in incidences of adverse events (AE) and serious adverse events (SAE) in either trial. In April 2025, AstraZeneca announced that its experimental oral PCSK9 inhibitor, AZD0780, achieved a 50.7% reduction in LDL cholesterol over 12 weeks when added to statin therapy. This positions it as a strong competitor to existing injectable PCSK9 inhibitors, offering the advantage of oral administration without the need for fasting In April 2025, Verve Therapeutics' stock surged by 12.27% in pre-market trading, driven by the company's announcement of promising trial results for its cholesterol drug, VERVE-102 In Febuary 2025, Despite previous approvals, inclisiran, a small interfering RNA therapy targeting PCSK9, was not included in the American Association of Clinical Endocrinology's 2025 guidelines for dyslipidemia management. The decision was based on limited evidence regarding its impact on cardiovascular outcomes In December 2024, LIB Therapeutics submitted a Biologics License Application (BLA) to the FDA for Lerodalcibep, seeking approval to lower LDL-C in patients with ASCVD, high ASCVD risk, and primary hyperlipidemia, including HeFH and HoFH. The PCSK9 Inhibitors Market in the 7MM was valued at approximately USD 2 billion in 2023, with the United States leading the market at around USD 900 million. In August 2023, The National Medical Products Administration (NMPA) of China has approved SINTBILO® (tafolecimab injection, anti-PCSK9 monoclonal antibody) for the treatment of adult patients with primary hypercholesterolemia, according to Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a renowned biopharmaceutical company that develops, produces, and sells premium medications for the treatment of oncology, autoimmune, metabolic SINTBILO® (tafolecimab injection), the company's tenth product in its commercial portfolio, is Innovent's first medication to enter the cardiovascular market and the first domestic PCSK9 inhibitor licenced in China In the United States, there were approximately 1,490,000 prevalent instances of FH in 2021, and this figure is anticipated to rise from 2020 to 2034 According to Hemphill et al. (2020), low-density lipoprotein (LDL) receptor gene mutations are the most frequent cause of homozygous familial hypercholesterolemia (HoFH), an inherited condition Around 1,275,000 instances of FH were widespread overall in EU-5 in 2021; this number is projected to rise from 2020 to 2034 The overall number of prevalent FH cases in Japan was at 363,700 in 2021, and it is anticipated that this number will rise from 2020 to 2034 Key PCSK9 Inhibitors Companies: Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotechnology, Novo Nordisk, AstraZeneca, Akeso Biopharma, Amgen, Jiangsu Hengrui Medicine Co., Innovent Biologics, LIB Therapeutics, AstraZeneca and Ionis Pharmaceuticals, CiVi Biopharma, and others Key PCSK9 Inhibitors Therapies: STP135G, PCSK9 inhibitor, VERVE 101, SAL-003, NNC 03850434, AZD 8233, AK102, Evolocumab, SHR-1209, Tafolecimab, LIB003 (Lerodalcibep), AZD8233 (ION449), Cepadacursen sodium (CIVI-007), CiVI-008, and others The PCSK9 Inhibitors market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage PCSK9 Inhibitors pipeline products will significantly revolutionize the PCSK9 Inhibitors market dynamics. PCSK9 Inhibitors Overview PCSK9 inhibitors are a class of cholesterol-lowering medications that target proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein involved in regulating low-density lipoprotein (LDL) cholesterol levels. These drugs are primarily used for patients with hypercholesterolemia or cardiovascular diseases who do not respond adequately to statins or cannot tolerate them. PCSK9 binds to LDL receptors on liver cells, leading to their degradation and reducing the liver's ability to remove LDL cholesterol from the bloodstream. By inhibiting PCSK9, these drugs increase the number of LDL receptors, enhancing the clearance of LDL cholesterol and significantly lowering its levels. Two FDA-approved PCSK9 inhibitors, alirocumab and evolocumab, are monoclonal antibodies administered via subcutaneous injection. They have been shown to reduce LDL cholesterol by up to 60% and lower the risk of major cardiovascular events, such as heart attacks and strokes. PCSK9 inhibitors are generally well-tolerated, with mild side effects like injection site reactions, flu-like symptoms, or upper respiratory tract infections. However, their high cost limits widespread use. These inhibitors represent a significant advancement in lipid management, particularly for patients with familial hypercholesterolemia or those at high cardiovascular risk. Ongoing research explores their potential broader applications and cost-effectiveness strategies. PCSK9 Inhibitors Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. PCSK9 Inhibitors Epidemiology Segmentation: The PCSK9 Inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of PCSK9 Inhibitors Prevalent Cases of PCSK9 Inhibitors by severity Gender-specific Prevalence of PCSK9 Inhibitors Diagnosed Cases of Episodic and Chronic PCSK9 Inhibitors Download the report to understand which factors are driving PCSK9 Inhibitors epidemiology trends @ PCSK9 Inhibitors Epidemiology Forecast PCSK9 Inhibitors Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the PCSK9 Inhibitors market or expected to get launched during the study period. The analysis covers PCSK9 Inhibitors market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the PCSK9 Inhibitors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. PCSK9 Inhibitors Therapies and Key Companies STP135G: Sirnaomics PCSK9 inhibitor: Vaxxinity VERVE 101: Verve Therapeutics SAL-003: Xinlitai Biotechnology NNC 03850434: Novo Nordisk AZD 8233: AstraZeneca AK102: Akeso Biopharma Evolocumab: Amgen SHR-1209: Jiangsu Hengrui Medicine Co. Tafolecimab: Innovent Biologics LIB003 (Lerodalcibep): LIB Therapeutics AZD8233 (ION449): AstraZeneca and Ionis Pharmaceuticals Cepadacursen sodium (CIVI-007): CiVi Biopharma CiVI-008: CiVi Biopharma Download the report to understand which factors are driving PCSK9 Inhibitors epidemiology trends @ PCSK9 Inhibitors Drugs and Therapies PCSK9 Inhibitors Market Strengths According to the World Heart Federation report, CVD alone, including heart disease and stroke, makes up nearly 50% of all non-communicable disease deaths. Prevention of CVD in high-risk patients by PCSK9 inhibition might help in relieving the high economic burden. PCSK9 Inhibitors Market Opportunities Though monoclonal antibodies have, for the time being, established themselves as the most clinically useful inhibitors of PCSK9, other novel therapies are currently in various stages of development. Scope of the PCSK9 Inhibitors Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key PCSK9 Inhibitors Companies: Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotechnology, Novo Nordisk, AstraZeneca, Akeso Biopharma, Amgen, Jiangsu Hengrui Medicine Co., Innovent Biologics, LIB Therapeutics, AstraZeneca and Ionis Pharmaceuticals, CiVi Biopharma, and others Key PCSK9 Inhibitors Therapies: STP135G, PCSK9 inhibitor, VERVE 101, SAL-003, NNC 03850434, AZD 8233, AK102, Evolocumab, SHR-1209, Tafolecimab, LIB003 (Lerodalcibep), AZD8233 (ION449), Cepadacursen sodium (CIVI-007), CiVI-008, and others PCSK9 Inhibitors Therapeutic Assessment: PCSK9 Inhibitors current marketed and PCSK9 Inhibitors emerging therapies PCSK9 Inhibitors Market Dynamics: PCSK9 Inhibitors market drivers and PCSK9 Inhibitors market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies PCSK9 Inhibitors Unmet Needs, KOL's views, Analyst's views, PCSK9 Inhibitors Market Access and Reimbursement To know more about PCSK9 Inhibitors companies working in the treatment market, visit @ PCSK9 Inhibitors Clinical Trials and Therapeutic Assessment Table of Contents 1. PCSK9 Inhibitors Market Report Introduction 2. Executive Summary for PCSK9 Inhibitors 3. SWOT analysis of PCSK9 Inhibitors 4. PCSK9 Inhibitors Patient Share (%) Overview at a Glance 5. PCSK9 Inhibitors Market Overview at a Glance 6. PCSK9 Inhibitors Disease Background and Overview 7. PCSK9 Inhibitors Epidemiology and Patient Population 8. Country-Specific Patient Population of PCSK9 Inhibitors 9. PCSK9 Inhibitors Current Treatment and Medical Practices 10. PCSK9 Inhibitors Unmet Needs 11. PCSK9 Inhibitors Emerging Therapies 12. PCSK9 Inhibitors Market Outlook 13. Country-Wise PCSK9 Inhibitors Market Analysis (2020–2034) 14. PCSK9 Inhibitors Market Access and Reimbursement of Therapies 15. PCSK9 Inhibitors Market Drivers 16. PCSK9 Inhibitors Market Barriers 17. PCSK9 Inhibitors Appendix 18. PCSK9 Inhibitors Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Globe and Mail
2 days ago
- Globe and Mail
Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing
OSAKA, Japan , /CNW/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary — a milestone that reflects two decades of dedication to improving health outcomes through high-quality, patient-centered research. Since its founding in 2005 in Japan , the company has grown from a small team with a bold vision into a global organization supporting clinical trials in more than 30 countries. From the beginning, Linical set out to do more than manage clinical studies — the company set out to make a meaningful impact on patients' lives. Over the years, Linical's services have expanded to include full-service clinical trial management, site selection and feasibility, regulatory support, biometrics, pharmacovigilance, and drug development strategies. Throughout this growth, Linical's core mission has remained the same: to advance science while prioritizing patient safety and wellbeing. "What began as a small startup with a few dedicated professionals from the pharmaceutical industry has grown into a global force in clinical research," said Kazuhiro Hatano , President and CEO of Linical. "We've never lost sight of the fact that at the heart of every clinical trial is a patient who is hoping for a better future. That's what continues to drive us." Over the past two decades, Linical has supported hundreds of clinical studies across a range of therapeutic areas including oncology, neurology, immunology, and rare diseases. By leveraging technology and data-driven processes, the company has delivered faster study start-up times, improved site performance, and enhanced trial quality. Its investments in decentralized trial capabilities and digital tools have positioned the company at the forefront of innovation, especially in an era where flexibility and accessibility in research are more critical than ever. The company attributes its success to a collaborative culture, strong partnerships with sponsors and sites, and an unwavering focus on patients. "Clinical research is ultimately about people," added Mr. Hatano. "It's about the people participating in trials, the investigators treating them, and the sponsors developing new therapies. We're proud to be part of that ecosystem, helping turn scientific discovery into real-world impact." As it marks its 20th year, Linical is also looking ahead. The arrival of artificial intelligence is transforming the clinical research industry. With continued investment in global operations, advanced analytics, and patient-focused technologies, the company plans to further strengthen its ability to deliver efficient, high-quality clinical trials that bring new treatments to market faster. "We're proud of what we've achieved, but we're even more excited about the future," said Mr. Hatano. "Our work is far from done, and we remain committed to our purpose: improving lives through research." About Linical: Linical is a global provider of clinical research services, supporting biopharmaceutical companies in bringing innovative therapies to patients across APAC, Europe , and North America . With a focus on quality, technology, and patient wellbeing, Linical delivers tailored solutions for clinical trials across all phases and numerous therapeutic areas.
Globe and Mail
2 days ago
- Globe and Mail
Facial Lines Market Set for Significant Transformation by 2032, Forecasts DelveInsight
"Facial Lines Market" Facial Lines Companies working in the market are Ipsen, Evolus, Inc., and others. (Albany, USA) DelveInsight's ' Facial Lines - Market Insight, Epidemiology, And Market Forecast - 2032 ″ report offers an in-depth understanding of the Facial Lines, historical and forecasted epidemiology as well as the Facial Lines market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Facial Lines market is experiencing steady advancements, driven by evolving treatment approaches and research innovations. DelveInsight's latest 7MM report provides comprehensive insights into key epidemiology trends and market dynamics. Some of the key facts of the Facial Lines Market Report: According to DelveInsight, the market for Facial Lines in the 7MM is expected to grow steadily from 2019 to 2032. According to the Global Burden of Disease Study 2019, the global incidence of orofacial clefts decreased from 237,258 cases in 1990 to 192,708 cases in 2019, with an age-standardized rate (ASR) reduction from 3.61 per 100,000 in 1990 to 2.98 per 100,000 in 2019. Ultraviolet (UV) light and sunlight exposure significantly accelerate skin aging, resulting in photoaging, which is responsible for 90% of visible skin changes. The wrinkle scale, rated on a 0-9 scale, is a valuable tool in research for evaluating different types of aesthetic procedures. Emerging drugs for aesthetic treatments include IPN10200, PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, and others. Leading companies in the aesthetic and dermatology market include Ipsen, Evolus, Inc., and others. Photoaging continues to be a significant factor in skin damage, driving the development of new treatments in the aesthetics industry. To Know in detail about the Facial Lines market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Facial Lines Market Forecast Facial Lines Overview Facial lines, commonly known as wrinkles, are visible creases or folds in the skin that develop due to aging, repetitive facial expressions, sun exposure, and other environmental and genetic factors. These lines can appear on different areas of the face, including the forehead, around the eyes (crow's feet), between the eyebrows (glabellar lines), and around the mouth (nasolabial folds and marionette lines). The primary cause of facial lines is the gradual decline in collagen and elastin production, which leads to reduced skin elasticity and firmness. Additionally, repeated muscle movements, such as frowning, smiling, or squinting, contribute to the formation of dynamic wrinkles, which may become static over time as the skin loses its ability to bounce back. External factors such as prolonged sun exposure, smoking, pollution, and poor skincare habits can accelerate the development of facial lines. While facial lines are a natural part of aging, various treatment options are available to minimize their appearance. These include topical treatments (retinoids, peptides, and hyaluronic acid-based creams), minimally invasive procedures (botulinum toxin injections, dermal fillers, and laser therapy), and more advanced interventions like chemical peels, microneedling, and facelift surgery. With increasing consumer demand for aesthetic procedures and advancements in dermatological treatments, the market for facial line reduction continues to grow, offering both preventive and corrective solutions to individuals seeking youthful, smoother skin. Facial Lines Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Facial Lines Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Facial Lines market or expected to be launched during the study period. The analysis covers the Facial Lines market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the activities of the facial lines pipeline development. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Facial Lines Market Strengths Growing consumer interest in non-invasive and minimally invasive cosmetic procedures, such as botulinum toxin injections and dermal fillers, is driving market expansion. Increasing social media influence and a focus on youthful appearances further fuel demand. Continuous improvements in anti-aging treatments, including next-generation fillers, laser therapies, and skincare formulations with peptides and hyaluronic acid, enhance treatment efficacy and patient satisfaction. Facial Lines Market Weaknesses Premium aesthetic procedures, such as laser resurfacing and high-end dermal fillers, can be expensive, limiting accessibility for a broader population, particularly in developing regions. Strict regulations on cosmetic injectables and emerging anti-aging treatments, along with concerns about side effects or complications, may hinder market growth and delay product approvals. Scope of the Facial Lines Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Facial Lines Therapies: IPN10200, PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, and others. Key Facial Lines Companies: Ipsen, Evolus, Inc., and others. Facial Lines Therapeutic Assessment: Facial Lines currently marketed and Facial Lines emerging therapies Facial Lines Market Dynamics: Facial Lines market drivers and Facial Lines market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Facial Lines Unmet Needs, KOL's views, Analyst's views, Facial Lines Market Access and Reimbursement To learn more about the key players and advancements in the Facial Lines Treatment Landscape, visit the Facial Lines Market Analysis Report Table of Contents 1. Facial Lines Market Report Introduction 2. Executive Summary for Facial Lines 3. SWOT analysis of Facial Lines 4. Facial Lines Patient Share (%) Overview at a Glance 5. Facial Lines Market Overview at a Glance 6. Facial Lines Disease Background and Overview 7. Facial Lines Epidemiology and Patient Population 8. Country-Specific Patient Population of Facial Lines 9. Facial Lines Current Treatment and Medical Practices 10. Facial Lines Unmet Needs 11. Facial Lines Emerging Therapies 12. Facial Lines Market Outlook 13. Country-Wise Facial Lines Market Analysis (2019–2032) 14. Facial Lines Market Access and Reimbursement of Therapies 15. Facial Lines Market Drivers 16. Facial Lines Market Barriers 17. Facial Lines Appendix 18. Facial Lines Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
